Comparison of median time for submission to EM countries from 1st world-wide approval (2006-2007 vs 2008-2009) Median time from 1st WW approval to submission.

Slides:



Advertisements
Similar presentations
Miscellaneous – Regions, Locations and Places Part IV.
Advertisements

UNIVERSITY OF JYVÄSKYLÄ INTERNATIONAL COOPERATION.
Brazil The UK Argentina USA Which country is this? Countries of the World.
Biopharmaceutical Regulatory Requirements 40. Marketing Authorization for New Chemical Entities Health Canada’s (HC) Therapeutic Products Directorate.
TRIPS Flexibilities Preventive Measures Johanna von Braun, PhD University of Cape Town, South Africa Kiev, 21/22 nd June, 2010.
Commodity Imports and Exports Click your way slowly through the next slides to see where certain commodities are exported from, and where they are imported.
1 Sovereign Credit Risk: Changing Fundamentals Fixed Income Forum March 25, 2010 Manmohan S. Kumar Assistant Director Fiscal Affairs Department International.
Developed vs. Developing Countries: What you need to know for the quiz.
DRUG DEVELOPMENT & REGULATIONS DR ARIF HASHMI. DRUG DEVELOPMENT Discovery and synthesis Preclinical development (chemical testing, biological testing,
Marine Drug Development and Delivery Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University College of Pharmacy BELGAUM ,
Stages of Economic Development
PHARMACOLOGY oScience of drugs oGreek words= pharmakon (drug) and logos (study) oDeals with interaction of exogenously administered chemical molecules.
Highest Return Lowest Return Turkey Czech Rep Russia Czech Rep Thailand.
S. Goto1, J. Zhu2, L. Lisheng2, BH. Oh3, D. Wojdyla4, M. Hanna5, J. Horowitz6, L. Wallentin7, D. Xavier8, JH. Alexander4 (1) Tokai University School of.
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
First Lecture By Dr. Abdelkader Ashour, Ph.D. Dr. Amira Badr, Ph.D.
CATCH UP AND EMERGING DIVERGENCES: Can it Reduce Inequality? Deepak Nayyar Institute of Social Studies The Hague 8th October 2015.
WARM UP:  Open your binder to page 34. With a partner, come up with a list of what you believe to be the most powerful and influential countries in the.
More Developed Countries Australia Canada France Germany Israel Italy Japan Norway Russia South Korea Spain Sweden Taiwan United Kingdom United States.
The United States The Economy. What is GDP ? Gross Domestic Product (GDP): The total market (or dollar) value of all final goods and services produced.
2016 Global Manufacturing Competitiveness Index. 2Deloitte and US Council on Competitiveness I 2016 Global Manufacturing Competitiveness IndexCopyright.
G8 Group of Eight. G8 G8 G Originally G7 - France, Germany, Italy, Japan, Britain, Canada and the U.S Originally G7 - France, Germany,
Differentiate between a mixture and a compound.. Key concepts/skills: Level 1: Define key vocabulary. Level 2: Given a substance, differentiate between.
Funding the future Финансирование предпринимательской деятельности в странах G20 Дмитрий Неверко.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Sodium Starch Glycolate Market Products, Applications & regional performance.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Sodium Starch Glycolate Market Products, Applications & regional performance.
Can Lebanon Compete in the Innovative Biopharmaceutical Sector?
Certification CS-100/ CSE-200 /CSC-1
Continents and Oceans.
Human Geography, Vogeler
Incheon (2009) Registration
10 Most Populated Country in the World.
The World Market.
The percentage of NASs approved by CDER
© 2017 Global Market Insights, Inc. USA. All Rights Reserved Organic Fertilizers Market Share, Application Potential, By Product, 2017.
© 2017 Global Market Insights, Inc. USA. All Rights Reserved Organic Fertilizers Market Share, Application Potential, By Product, 2017.
NASs approval time by therapeutic area:
Median 25th and 75th percentile
Citi Virtual Card Accounts – Continued Global Expansion
Median approval time for new active substances approved by ICH agencies by approval year Methodology For each new active substance (NAS) approved between.
Performance of healthcare stocks versus all stocks (emerging market sample). Performance of healthcare stocks versus all stocks (emerging market sample).
Comparing HTA recommendations
Characteristics of a State
Percentage Key Message
2002–2006 Mid and Other sized companies continued to launch the majority of NMEs APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON.
Characteristics of a State
Median submission gap, median approval time and percentage approved as expedited for new active substances (NASs) approved by six authorities:
Asian Tigers, NICs, and BRICS
Median time to internationalisation
This study was conducted using the CIRS EMaRReT database, which tracks new medicines and line extensions in 15 Emerging Markets (Argentina, Brazil, Mexico,
INTRODUCTION to Pharmacology
Comparison of median time for submission to EM countries from 1st world-wide approval ( vs ) Median time from 1st WW approval to submission.
New active substance median approval time for six regulatory authorities in Key messages The last decade, , saw a continuation.
New active substances approved by EMA and FDA over 10 years
EMA: The European Medicines Agency
NME/NAS launches in 2005/6 APRIL 2007
Rollout time breakdown: 24 common NASs in 7 jurisdictions
INTERNATIONALISATION – FOCUS ON EMA AND FDA
Characteristics of A State
Development time for new molecular entities first launched onto the world market between MARCH 2008 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS.
Cycle times decreased in larger but not smaller, companies
By Amany Helmy Hasanin Assistant Professor of Clinical Pharmacology
Opening an IND: Investigator Perspective
Assessment routes and timelines in Australia (2011)
Characteristics of A State
Characteristics of a State
Global Commercial Agriculture
Out of the 52 NASs approved by all six authorities during :
Median times to submission and licensing for 70 new active substances approved in five markets from 1997 to 2010 Note: EMA approval.
Assessment routes and timelines
Presentation transcript:

Comparison of median time for submission to EM countries from 1st world-wide approval (2006-2007 vs 2008-2009) Median time from 1st WW approval to submission in EM country for NAS submitted 2008-2009 Argentina The slide shows a the submission lag time to Emerging Market countries after first world-wide approval, when comparing two-year cohorts ( 2006-2007 vs 2008-2009). These data shows that the time to submission in Russia, India and to some extent China, was faster in 2008-2009 compared with 2006-2007. Submission timing to Brazil, Mexico, Turkey, Indonesia, South Africa. Taiwan and Argentina, however, was slower in 2008-2009 compared with 2006-2007. Those countries that are depicted as close to the line of identity show little or no change to the median submission time in those time periods. Source: CIRS Emerging Markets Regulatory Review times (EMaRRet) database New Active Substances (NAS): This includes chemical, biological and radiopharmaceutical substances that have not been previously available for therapeutic use in humans to be used for the cure, alleviation, treatment, prevention or in vivo diagnosis of diseases in humans. This term also includes: An isomer, mixture of isomers, a complex or derivative or salt of a chemical substance previously available as a medicinal product but differing in properties with regard to safety and efficacy from that substance previously available; a biological substance previously available as a medicinal product, but differing in molecular structure, nature of source material or manufacturing process; a radiopharmaceutical substance that is a radionuclide or a ligand not previously available as a medicinal product. Alternatively, the coupling mechanism linking the molecule and the radionuclide has not been previously available. Median time from 1st WW approval to submission in EM country for NAS submitted 2006-2007 BRICK TM countries Non- BRICK TM countries